Skip to main content
Top
Published in:

Open Access 25-06-2024 | Adverse Effects of Cancer Therapy | Case Report

Thoracic lymphangitis as an immune-related adverse event: a case report

Author: Haruki Kobayashi

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

The efficacy of immune checkpoint inhibitors (ICIs) has been widely recognized in several cancers and is now being used in the perioperative setting for lung cancer.
We recently encountered an immune-related adverse event that has not been previously reported: thoracic lymphangitis, which occurred after postoperative ICI treatment for lung cancer. The patient complained of breathlessness and her condition rapidly progressed to hypoxia grade 3. Chest computed tomography revealed significant lymphostasis. With high-dose steroid treatment, the patient showed improvement.
Therefore, as the frequency of neoadjuvant, adjuvant, and perioperative ICI use is expected to increase, it is crucial to understand and monitor this adverse event.
Literature
1.
go back to reference Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344–57.CrossRefPubMed Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344–57.CrossRefPubMed
2.
go back to reference O’Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23:1274–86.CrossRefPubMed O’Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23:1274–86.CrossRefPubMed
4.
5.
6.
go back to reference Takada K, Takamori S, Brunetti S, et al. Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non–small-cell lung cancer: a systematic review. Clin Lung Cancer. 2023;24:581–90.CrossRefPubMed Takada K, Takamori S, Brunetti S, et al. Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non–small-cell lung cancer: a systematic review. Clin Lung Cancer. 2023;24:581–90.CrossRefPubMed
Metadata
Title
Thoracic lymphangitis as an immune-related adverse event: a case report
Author
Haruki Kobayashi
Publication date
25-06-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-03123-5

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue